US FDA rejects pimavanserin (Nuplazid) for dementia-related psychosis

The FDA notes a lack of statistical significance in some of the dementia subgroups in the Phase III HARMONY study. The company states the study met prespecified endpoints, and that statistical separation by dementia subgroups was not a prespecified requirement.

Source:

Biospace Inc.